Find us on:


Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report

Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Publication Type
Journal Article
Research Type
Reported as
Case Report/Series/Restrospective Study
July 15, 2018
George Muller, Robert Grieshaber, Floyd Talley, Mike Riepl, Don Fellows
Compounding Business Services; Grieshaber Dermatology; Floyd's Family Pharmacy; Gateway Pharmacy

The ancient autoimmune skin condition psoriasis is still ubiquitous worldwide, produces the same, often-intolerable effects noted in its earliest recorded descriptions, and remains without cure. Management options designed to resolve the itchy, scaly, weeping, erythematous, and often widespread lesions of that disorder are now available, but they vary in efficacy, most are associated with the development of severe adverse effects, and many are prohibitively expensive. In this article, we describe the successful use of a compounded formulation of oral low-dose naltrexone to manage guttate psoriasis in a 75-year-old white male patient. That therapy produced only 1 adverse effect (dry skin near the lesions on the patient's arms and legs) and was relatively inexpensive. The formulation for that preparation and comments from the patient, the pharmacist who suggested its use, the prescriber, and the compounder who prepared it are included. Many clinicians are unaware of the benefits of compounded low-dose naltrexone in treating autoimmune diseases. We hope that this case report will encourage compounding pharmacists to consider and suggest it as an alternative therapy for patients who cannot tolerate or afford manufactured medications to treat psoriasis.